In conclusion, the Scn1aWT/R613X DS model, harboring the recurrent nonsense Scn1a mutation and available in open access distribution, including to for-profit organizations through The Jackson Laboratory (Strain no. 034129), demonstrates multiple Dravet-associated phenotypes with robust and specific deficits that can be used as a preclinical model for drug development. This evidence concerns the gene SCN1A and Dravet syndrome.